Current Hypertension Reports

, Volume 10, Issue 3, pp 222–226 | Cite as

Obesity, sleep apnea, aldosterone, and hypertension



The pathogenesis of hypertension associated with obesity is unclear. This review provides evidence supporting excess visceral fat as an early aspect, and obstructive sleep apnea and elevated levels of aldosterone as factors closer to hypertension in the mechanistic chain. Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here. Possible therapeutic interventions addressing the hypertension associated with obesity are briefly mentioned.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Morse SA, Zhang R, Thakur V, Reisin E: Hypertension and the metabolic syndrome. Am J Med Sci 2005, 330:303–310.PubMedCrossRefGoogle Scholar
  2. 2.
    Lambert E, Straznicky N, Schlaich M, et al.: Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension 2007, 50:862–868.PubMedCrossRefGoogle Scholar
  3. 3.
    Mancia G, Bousquet P, Elghozi JL, et al.: The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007, 25:909–920.PubMedCrossRefGoogle Scholar
  4. 4.
    DiBona GF: dynamic analysis of patterns of renal sympathetic nerve activity: implications for renal function. Exp Physiol 2005, 90:159–161.PubMedCrossRefGoogle Scholar
  5. 5.
    Correia ML, Haynes WG: Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004, 13:215–223.PubMedCrossRefGoogle Scholar
  6. 6.
    Dancey DR, Hanly PJ, Soong C, et al.: Gender differences in sleep apnea: the role of neck circumference. Chest 2003, 123:1544–1550.PubMedCrossRefGoogle Scholar
  7. 7.
    Morgan BJ: Pathophysiology of sleep apnea. In Hypertension Primer, edn 4. Edited by Izzo JL, Sica DA, Black HR. Philadelphia: Lippincott Williams and Wilkins; 2008:174–176.Google Scholar
  8. 8.
    Boggia J, Thijs L, Hansen TW, et al.: Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007, 370:1219–1229.PubMedCrossRefGoogle Scholar
  9. 9.
    Norman D, Loredo JS, Nelesen RA, et al.: Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 2006, 47:840–845.PubMedCrossRefGoogle Scholar
  10. 10.
    Hla KM, Skatrud JB, Finn L, et al.: The effect of correction of sleep-disordered breathing on BP in untreated hypertension. Chest 2002, 122:1125–1132.PubMedCrossRefGoogle Scholar
  11. 11.
    Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004, 43:1–7.Google Scholar
  12. 12.
    Egan BM, Stepniakowski K, Goodfriend TL: Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 1994, 7:886–893.PubMedGoogle Scholar
  13. 13.
    Calhoun DA, Nishizaka MK, Zaman MA, Harding SM: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112–117.PubMedCrossRefGoogle Scholar
  14. 14.
    Aguilera G, Kiss A, Lu A, Camacho C: Regulation of adrenal steroidogenesis during chronic stress. Endocr Res 1996, 22:433–443.PubMedGoogle Scholar
  15. 15.
    Hiramatsu K, Yamada T, Ichikawa K, et al.: Changes in endocrine activities relative to obesity in patients with essential hypertension. J Am Geriatr Soc 1981, 29:25–30.PubMedGoogle Scholar
  16. 16.
    Rocchini AP, Katch VL, Grekin R: Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986, 57:613–618.PubMedCrossRefGoogle Scholar
  17. 17.
    Goodfriend TL, Egan BM, Kelley DE: Aldosterone in obesity. Endocr Res 1998, 24:789–796.PubMedCrossRefGoogle Scholar
  18. 18.
    Licata G, Volpe M, Scaglione R, Rubattu S: Salt-regulating hormones in young normotensive obese subjects: effects of saline load. Hypertension 1994, 23:I20–I24.PubMedGoogle Scholar
  19. 19.
    Krieger J, Follenius M, Sforza E, et al.: Effects of treatment with nasal continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea. Clin Sci 1991, 80:443–449.PubMedGoogle Scholar
  20. 20.
    Makhanova N, Hagaman J, Kim J-S, Smithies O: Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension 2008, 51:134–140.PubMedCrossRefGoogle Scholar
  21. 21.
    Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925–930.PubMedCrossRefGoogle Scholar
  22. 22.
    Ouzan J, Péraut C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333–339.PubMedCrossRefGoogle Scholar
  23. 23.
    Stanley AG, Swales P, Thurston H, Williams B: Treating resistant hypertension in type 2 diabetes: a role for spironolactone. Br J Diabetes Vasc Dis 2006, 6:90–92.CrossRefGoogle Scholar
  24. 24.
    Sharabi Y, Adler E, Shamis A, et al.: Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 2006, 19:750–755.PubMedCrossRefGoogle Scholar
  25. 25.
    Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839–845.PubMedCrossRefGoogle Scholar
  26. 26.
    Ritchie SA, Connell JM: The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007, 17:319–326.PubMedCrossRefGoogle Scholar
  27. 27.
    Goodfriend TL, Egan B, Stepniakowski K, Ball DL: Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995, 25:30–36.PubMedGoogle Scholar
  28. 28.
    Vogt B, Bochud M, Burnier M: The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol 2007, 27:529–537.PubMedCrossRefGoogle Scholar
  29. 29.
    Goodfriend TL: Aldosterone: a hormone of cardiovascular adaptation and maladaption. J Clin Hypertens 2006, 8:133–139.CrossRefGoogle Scholar
  30. 30.
    Adler GK, Williams GH: Aldosterone: villain or protector? Hypertension 2007, 50:31–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Fox CS, Massaro JM, Hoffmann U, et al.: Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007, 116:39–48.PubMedCrossRefGoogle Scholar
  32. 32.
    Andrew R, Westerbacka J, Wahren J, et al.: The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005, 54:1364–1370.PubMedCrossRefGoogle Scholar
  33. 33.
    Kannisto K, Pietiläinen KH, Ehrenborg E, et al.: Over-expression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studied in young adult monozygotic twins. J Clin Endocrinol Metab 2004, 89:4414–4421.PubMedCrossRefGoogle Scholar
  34. 34.
    Engeli S, Böhnke J, Feldpausch M, et al.: Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004, 12:9–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Paulsen SK, Pedersen SB, Fisker S, Richelsen B: 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007, 15:1954–1960.CrossRefGoogle Scholar
  36. 36.
    Goodfriend TL, Ball DL, Egan BM, et al.: Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004, 43[part 2]:358–363.PubMedCrossRefGoogle Scholar
  37. 37.
    Schinner S, Willenberg HS, Krause D, et al.: Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007, 31:864–870.Google Scholar
  38. 38.
    Catena C, Lapenna R, Baroselli S, et al.: Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006, 91:3457–3463.PubMedCrossRefGoogle Scholar
  39. 39.
    Hitomu H, Kiyomoto H, Nishiyama A, et al.: Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007, 50:750–755.CrossRefGoogle Scholar
  40. 40.
    Rondinone CM, Rodbard D, Baker ME: Aldosterone stimulates differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 1993, 132:2421–2426.PubMedCrossRefGoogle Scholar
  41. 41.
    Wolk R, Shamsuzzaman ASM, Somers VK: Obesity, sleep apnea, and hypertension. Hypertension 2003, 42:1067–1074.PubMedCrossRefGoogle Scholar
  42. 42.
    Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al.: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453–459.PubMedCrossRefGoogle Scholar
  43. 43.
    Nagase M, Matsui H, Shibata S, et al.: Salt-induced nephropathy in obese spontaneously hypersensitive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 2007, 50:877–883.PubMedCrossRefGoogle Scholar
  44. 44.
    Engeli S, Böhnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356–362.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Research ServiceWilliam S. Middleton Memorial Veterans HospitalMadisonUSA

Personalised recommendations